TWC
ORMP icon

TD Waterhouse Canada’s Oramed Pharmaceuticals ORMP Stock Holding History

TD Waterhouse Canada’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$2.55K – 1779
2023
Q3 		$2.55K Hold
1,000
– – ﹤0.01% 1470
2023
Q2 		$3.57K Buy
+1,000
New +$3.21K ﹤0.01% 1450

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TD Waterhouse Canada's ORMP Position: Q4 2023 in Review

TD Waterhouse Canada sold out of Oramed Pharmaceuticals (ORMP) in Q4 2023, closing a stake of 1,000 shares — an estimated $2.55K sold.

TD Waterhouse Canada first reported a position in ORMP in Q2 2023 and held it in 2 quarters. The position peaked at $3.57K in Q2 2023. 56 funds tracked by Wall St. Rank hold ORMP as of Q4 2023.

  • TD Waterhouse Canada reported no remaining Oramed Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • TD Waterhouse Canada sold 1,000 Oramed Pharmaceuticals shares in Q4 2023, an estimated $2.55K.
  • TD Waterhouse Canada first reported a position in Oramed Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • TD Waterhouse Canada's Oramed Pharmaceuticals position peaked at $3.57K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2023.

Based on TD Waterhouse Canada's 13F filing for Q4 2023, filed 12 Feb 2024.